Publications tagged with “survival analysis”
A statistical methodology that uses follow-up time to estimate time to event and hazard.
- Long MD, Ball K, Bocage C, Kappelman MD, Pipkin CA, Parlett LE. Novel therapies for inflammatory bowel disease and risks for non-melanoma skin cancer. Podium presented at: 2025 Digestive Disease Week; May 03 – May 06, 2025; San Diego, CA, US .
- Parlett LE, Ball K, Pipkin CA, Kappelman MD, Bocage C, Long MD. Compared to thiopurines and tumor necrosis factor inhibitors novel biologics are associated with reduced risk of non-melanoma skin cancer among patients with inflammatory bowel disease. Poster presented at: 2024 International Society for Pharmacoepidemiology Annual Meeting; Aug 24 – Aug 28, 2024; Berlin, DE .
- Singh S, Li X, Cocoros NM, et al. High-risk medications in persons living with dementia: a randomized clinical trial. Jama Intern Med. 2024; 184 (12) :1426-33 doi: 10.1001/jamainternmed.2024.5632.
- Adimadhyam S, Lewis JD, Simon AL, et al. Real-world evidence comparing tofacitinib and vedolizumab in anti-TNF-experienced patients with ulcerative colitis. Inflamm Bowel Dis. 2024; 30 (4) :554-62 doi: 10.1093/ibd/izad115.
- Kappelman MD, Adimadhyam S, Hou L, et al. Real-world evidence comparing vedolizumab and ustekinumab in antitumor necrosis factor-experienced patients with crohn's disease. Am J Gastroenterol. 2023; 118 (4) :674-84 doi: 10.14309/ajg.0000000000002068.